Artisan Partners Limited Partnership raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.2% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 595,526 shares of the biopharmaceutical company’s stock after buying an additional 55,103 shares during the period. Artisan Partners Limited Partnership’s holdings in Gilead Sciences were worth $40,448,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Rockland Trust Co. boosted its stake in shares of Gilead Sciences by 16.7% in the first quarter. Rockland Trust Co. now owns 178,245 shares of the biopharmaceutical company’s stock valued at $12,106,000 after buying an additional 25,551 shares in the last quarter. Linscomb & Williams Inc. boosted its stake in shares of Gilead Sciences by 3.0% in the first quarter. Linscomb & Williams Inc. now owns 5,275 shares of the biopharmaceutical company’s stock valued at $358,000 after buying an additional 154 shares in the last quarter. Berkshire Asset Management LLC PA acquired a new stake in shares of Gilead Sciences during the first quarter valued at about $270,000. Sigma Planning Corp boosted its stake in shares of Gilead Sciences by 7.7% in the first quarter. Sigma Planning Corp now owns 40,168 shares of the biopharmaceutical company’s stock valued at $2,728,000 after buying an additional 2,889 shares in the last quarter. Finally, Hollencrest Securities LLC boosted its stake in shares of Gilead Sciences by 119.8% in the first quarter. Hollencrest Securities LLC now owns 7,723 shares of the biopharmaceutical company’s stock valued at $525,000 after buying an additional 4,210 shares in the last quarter. Hedge funds and other institutional investors own 74.06% of the company’s stock.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at 73.44 on Tuesday. The company’s 50-day moving average is $70.60 and its 200-day moving average is $68.59. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $82.10. The stock has a market cap of $95.91 billion, a PE ratio of 7.98 and a beta of 1.21.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. During the same quarter in the previous year, the business posted $3.08 EPS. The firm’s revenue was down 8.2% on a year-over-year basis. Equities analysts anticipate that Gilead Sciences, Inc. will post $8.76 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.83%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.

TRADEMARK VIOLATION NOTICE: “Artisan Partners Limited Partnership Acquires 55,103 Shares of Gilead Sciences, Inc. (GILD)” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/08/08/artisan-partners-limited-partnership-acquires-55103-shares-of-gilead-sciences-inc-gild.html.

GILD has been the topic of several recent research reports. Zacks Investment Research upgraded shares of Gilead Sciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 11th. William Blair restated an “outperform” rating on shares of Gilead Sciences in a research report on Friday, June 16th. Morgan Stanley restated an “equal weight” rating on shares of Gilead Sciences in a research report on Tuesday, July 11th. Credit Suisse Group restated an “outperform” rating and set a $79.00 target price on shares of Gilead Sciences in a research report on Friday, May 5th. Finally, Leerink Swann restated a “hold” rating and set a $74.00 target price on shares of Gilead Sciences in a research report on Tuesday, July 25th. Eleven equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $80.31.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the completion of the transaction, the insider now owns 3,199,969 shares in the company, valued at approximately $242,749,648.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total transaction of $355,300.00. Following the transaction, the executive vice president now owns 102,988 shares of the company’s stock, valued at approximately $7,318,327.28. The disclosure for this sale can be found here. Insiders have sold a total of 206,666 shares of company stock valued at $15,223,184 in the last quarter. 1.30% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.